NCT03406104View on ClinicalTrials.gov

RESCUE and REVERSE Long-term Follow-up

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

July 4, 2022

Study Completion Date

July 4, 2022

Conditions
Leber Hereditary Optic Neuropathy
Interventions
GENETIC

GS010

Lenadogene nolparvovec Intravitreal ocular unilateral Injection

OTHER

Sham Intravitreal Injection

Lenadogene nolparvovec Intravitreal ocular unilateral Injection

Trial Locations (7)

19107

Wills Eye Institute, Philadelphia

30322

Emory University Hospital, Atlanta

40139

Ospedale Bellaria, Bologna

75012

CHNO Les Quinze Vingts, Paris

80336

LMU Klinikum der Universität München / Friedrich-Baur-Institut, Munich

91105

Doheny Eye Center UCLA, Pasadena

EC1V 2PD

Moorfields Eye Hospital, London

Sponsors

Lead Sponsor

GenSight Biologics
All Listed Sponsors
lead

GenSight Biologics

INDUSTRY